Renal Functional State in Patients with Chronic Heart Failure with Mid-Range Ejection Fraction

Authors

Daminov B.T.

Tashkent State Medical University, Tashkent, Uzbekistan
Asadov N.Z.

Republican Specialized Scientific-Practical Medical Center of Nephrology and Kidney Transplantation, Tashkent, Uzbekistan

DOI:

https://doi.org/10.37547/ajbspi/Volume06Issue05-04

Keywords:

Chronic heart failure mid-range ejection fraction renal dysfunction microalbuminuria

Abstract

Objective: To investigate renal functional parameters in patients with chronic heart failure with mid-range ejection fraction (HFmrEF) and to evaluate the clinical significance of renal dysfunction (RD) in this population.

Methods: A total of 88 male patients with post-infarction cardiosclerosis (PICS) and HFmrEF (NYHA functional class II–III) were prospectively enrolled and divided into two groups based on the presence of renal dysfunction.

Results: Patients with concomitant RD demonstrated a significant reduction in glomerular filtration rate (GFR) by 23.0% (P<0.01) and an elevation in serum creatinine by 21.8% (P<0.01) compared with patients without RD. Microalbuminuria was detected in 86.7% of RD patients. Analysis of cardiorenal correlations revealed significant associations between GFR and left ventricular ejection fraction, diastolic function indices, and remodelling parameters.

Conclusion: Renal dysfunction aggravates the clinical course of HFmrEF and is independently associated with worsened cardiac functional state. The established cardiorenal correlations underscore the importance of systematic renal function assessment in patients with HFmrEF.

References

Asghari G., Yuzbashian E., Mirmiran P., Azizi F. The association between Dietary Approaches to Stop Hypertension and incidence of chronic kidney disease in adults: the Tehran Lipid and Glucose Study. Nephrol Dial Transplant. 2017;32(Suppl 2):224–30. DOI: 10.1093/ndt/gfw273.

Authors Group. Clinical recommendations: Chronic heart failure. Russian Society of Cardiology. Russian Journal of Cardiology. 2020;25(11):40–83. DOI: 10.15829/1560-4071-2020-4083.

Atakhodjaeva G., Mirzaeva B. Kidney dysfunction in patients with chronic heart failure with metabolic syndrome. Chin J Ind Hyg Occup Dis. 2022;40(13):698–701. DOI: 10.5281/zenodo.7092923.

Atakhodjaeva G., Aripova J. The state of endothelial function in patients with chronic heart failure with various manifestations of the metabolic syndrome. J Hunan Univ Nat Sci. 2022. Available at: https://johuns.net/index.php/abstract/396.html.

Atakhodjaeva G., Azamov R., Akbarova G. The role of metabolic syndrome in the nature of post-infarction remodelling of the heart in patients with chronic heart failure. Texas J Med Sci. 2023;24:27–30.

Carrero J.J., Thomas F., Nagy K., et al. Global prevalence of protein-energy wasting in kidney disease: a meta-analysis of contemporary observational studies. J Ren Nutr. 2018;28(6):380–92. DOI: 10.1053/j.jrn.2018.08.006.

Damman K., Valente M.A., Voors A.A., O’Connor C.M., van Veldhuisen D.J., Hillege H.L. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–469. DOI: 10.1093/eurheartj/eht386.

Kamilova U., Abdullaeva Ch., Beknazarova S., et al. Disorders of kidney function in chronic heart failure. Indian J Forensic Med Toxicol. 2021;15(4):1547–1552.

Kovesdy C.P., Matsushita K., Sang Y., et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39:1535–42. DOI: 10.1093/eurheartj/ehy100.

Moiseev V.S., Mukhin N.A., Smirnov A.V., et al. Cardiovascular risk and chronic kidney disease: cardionephroprotection strategies. Russian J Cardiol. 2014;(8):7–37. DOI: 10.15829/1560-4071-2014-8-7-37.

Polyakov D.S., Fomin I.V., Belenkov Yu.N., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Cardiology. 2021;61(4):4–14.

Liu Y.H., Li K., Tian H.Q. Renoprotective effects of a new free radical scavenger, XH-003, against cisplatin-induced nephrotoxicity. Oxid Med Cell Longev. 2020;2020:9820168. DOI: 10.1155/2020/9820168.

Li J., Liu H., Takagi S., et al. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight. 2020;5(6):e129034. DOI: 10.1172/jci.insight.129034.

Reutens A.T., Jandeleit-Dahm K., Thomas M., et al. A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion. Contemp Clin Trials. 2020;90:105892. DOI: 10.1016/j.cct.2019.105892.